11.03.2024 - Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA in Glaucoma Expected in Q2 2024 Cash .
Ocular Therapeutix™ Reports Fourth Quarter And Full Year 2023 Results menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Operator: Good day. Thank you for standing by. Welcome to the Third Quarter 2023 Ocular Therapeutix Earnings Conference Call. At this time, all participants are in a listen-only mode.